ADMA BIOLOGICS, INC. (ADMA) Stock
9 of the hedge funds AlphaScala tracks reported ADMA in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is D.E. Shaw's at $44.15M. Company insiders reported 0 open-market buys and 2 sales on SEC Form 4 in the 90 days to Nov 5, 2026.
Which hedge funds own ADMA?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| D.E. Shaw David Shaw | 5.27M | $44.15M | +841% |
| Duquesne Family Office Stanley Druckenmiller | 2.78M | $23.30M | +80% |
| Fundsmith Terry Smith | 1.65M | $13.81M | n/a |
| Citadel Ken Griffin | 1.37M | $11.47M | -76% |
| Millennium Management Israel Englander | 1.15M | $9.66M | -66% |
| Renaissance Technologies Jim Simons (founder) | 653K | $5.46M | -48% |
| Point72 Steve Cohen | 414K | $3.46M | -87% |
| Bridgewater Associates Ray Dalio | 401K | $3.36M | -15% |
| Marshall Wace | 307K | $2.57M | NEW |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are ADMA BIOLOGICS, INC. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Nov 5, 26 | Grossman Adam S | President and CEO | SELL | 105.0K | $1.3M |
| Nov 5, 26 | Grossman Adam S | President and CEO | SELL | 42.0K | $504K |
SEC Form 4 filings as of Nov 5, 2026
See cluster-buy signals across all tickers →ADMA price chart
Powered by TradingViewWhat does ADMA BIOLOGICS, INC. do?
ADMA Biologics Inc. is a biopharmaceutical company that develops, manufactures, and markets specialty plasma-derived biologics for treating immune deficiencies and infectious diseases in the United States and internationally. Its primary products include BIVIGAM and ASCENIV, both intravenous immune globulin (IVIG) therapies indicated for primary humoral immunodeficiency (PI), and Nabi-HB, a human polyclonal antibody product for acute exposure to Hepatitis B. The company operates through segments including ADMA BioManufacturing for immune globulin production and development, Plasma Collection Centers for source plasma, and corporate overhead. ADMA Biologics Inc. maintains a fully U.S.-based, vertically integrated supply chain, encompassing plasma collection, manufacturing, and commercialization. It also sells plasma-derived intermediate fractions and provides laboratory contracting services. Founded in 2004 and headquartered in Ramsey, New Jersey, with additional facilities in Boca Raton, Florida, ADMA Biologics Inc. focuses on serving immunodeficient patients and those at risk for specific infections through its end-to-end commercial operations.